ClinicalTrials.gg
RecruitingNCT07855211HORIZONUpdated Nov 12, 2026

A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

A Phase 1/2 interventional study of BIIB147 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Biogen. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Biogen · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 12, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.

Started
2026
with 1 other
Phase 1/2
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 11th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyotrophic Lateral Sclerosis by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the effects of BIIB147, in participants with amyotrophic lateral sclerosis, also known as ALS. ALS is a rare disease that damages the motor neurons in the brain and spinal cord that help control the movement of muscles in the body. It is a progressive disease, which means that it gets worse with time. Over time, this causes increasing problems with speaking, swallowing, moving the arms and legs, and breathing. In the case of ALS, this eventually leads to death from patients not being able to breathe.

This is a "first-in-human" study. This means that this study drug will be given to people for the very first time in this study. These studies are important because they help researchers learn about the safety of the study drug, how the body processes it, and what dose might be appropriate before testing it in larger groups.

The main goal of the study is to learn about the safety of BIIB147 in adult participants with ALS. The main question researchers want to answer is:

  • How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
  • Researchers will also learn more about:

    • How much BIIB147 gets into the blood?
    • What is the highest amount of BIIB147 found in the blood?
    • How long does it take BIIB147 to reach its highest amount in the blood?
    • How much neurofilament light chain (NfL) protein is found in the blood?
    • How longer-term treatment with BIIB147 affects disease worsening and the participants' overall survival?

This study will be done as follows:

  • Participants will join the study after signing an informed consent form, also known as an ICF.
  • Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks.
  • Participants will be randomly assigned to get either the study drug BIIB147 or a placebo during the main treatment period. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given the same as the study drug.
  • Neither the participants nor the researchers will know if participants are getting the study drug or the placebo.
  • BIIB147 or the placebo will be given through a lumbar puncture. This is done using a thin needle that is put into the lower part of the spine.
  • During the main treatment period, participants will have regular clinic visits and phone calls. At the visits, the study doctor will do tests to check the participants' overall health, including their brain and nerve function. The participants' breathing function, tongue strength, and muscle strength will also be checked. They will also measure the participants' height, weight, and vital signs and collect blood and urine samples. Participants will also complete questionnaires or answer questions about how they are feeling and about their daily lives.
  • After finishing treatment in the main part of the study, some participants who qualify may be able to join a "long-term extension" part of the study. This may last up to 6 years or more. During this part of the study, all participants will get BIIB147.
  • After the long-term extension is done, participants will join a follow-up safety period. If participants do not enter the long-term extension, they will go directly into the follow-up safety period once the treatment period is done.
  • Each participant will be in the study for up to 8 years or more.
Read the detailed description

The primary objectives of this study are to evaluate the safety and tolerability of BIIB147 during the MAD Period and the long-term safety and tolerability of BIIB147 during the Open Label Extension (OLE) and the Integrated MAD and OLE Periods.

The secondary objectives of MAD Period are to evaluate the pharmacokinetics (PK) profile of total active BIIB147 related species in serum and cerebrospinal fluid (CSF), and to evaluate the impact of BIIB147 on neurodegeneration. The secondary objective for the OLE is to evaluate the long-term PK profile of total active BIIB147 related species in serum and CSF. The secondary objectives of the Integrated MAD Period and OLE are to evaluate the long-term impact of BIIB147 on neurodegeneration, on clinical outcomes of disease progression and survival for participants with earlier initiation of BIIB147 (i.e., start of MAD), compared with delayed initiation of BIIB147 (i.e., at start of the OLE), and long-term PK profile of total active BIIB147 related species in serum and CSF.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

MAD Period

  • Participants must have a diagnosis of ALS consistent with the Gold Coast criteria.
  • No pathogenic variants, likely pathogenic variants, or variants of uncertain significance in the superoxide dismutase 1 (SOD1) or fused in sarcoma (FUS) genes (confirmed by central genetic testing).
  • Greater than or equal to (≥) 50% of predicted value for slow vital capacity (SVC) as adjusted for sex, age, and height (from the sitting position).
  • If taking riluzole, participant must be on a stable dose for ≥ 30 days prior to Day 1 and expected to remain at that dose until the final study visit end of study (EOS)/early termination (ET), unless the Investigator determines that it should be discontinued for medical reasons, in which case it may not be restarted during the study.

OLE

  • Participants must have completed Study 303AS101 MAD period; all pre-dose assessments for the end of MAD treatment period visit (Day 113 for Cohorts A, B, C, and Day 169 for Cohort D) must be completed prior to dosing in OLE.

Key Exclusion Criteria:

MAD Period

  • History or positive test result at screening for (HIV). The requirement for testing at screening may be omitted if it is not permitted by local regulations.
  • History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NfL, in the opinion of the Investigator.
  • Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system during the study period.
  • Requires permanent ventilation (using > 22 hours per day [h/day] invasive or non-invasive ventilation)
  • History of a deep venous thrombosis or pulmonary embolism ≤2 years of screening, or since the date of ALS diagnosis, whichever is longer.
  • Treatment with an approved ALS disease-modifying therapy other than riluzole or edaravone, or another drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer, before completion of Screening.
  • Current enrollment or a plan to enroll in any interventional clinical study. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator and after consultation with the Sponsor.

OLE

  • Any new condition or worsening of an existing condition that, according to the Investigator, would make the participant unsuitable for inclusion, could interfere with the assessment of safety, or would compromise the ability of the participant to undergo study procedures.
  • abnormalities (based on most recent assessments in MAD period) in hematology, blood chemistry parameters, or 12-lead (ECG) prior to first OLE visit that would make the participant unsuitable for inclusion as assessed by the Investigator.

Note: Other protocol-defined Inclusion/Exclusion criteria do apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    MAD: Cohort A

    Participants will either receive Dose A of BIIB147 or a placebo for 12 weeks.

    Drug: BIIB147 · Drug: Placebo

  • Experimental
    MAD: Cohort B

    Participants will either receive Dose B of BIIB147 or a placebo for 12 weeks.

    Drug: BIIB147 · Drug: Placebo

  • Experimental
    MAD: Cohort C

    Participants will either receive Dose C of BIIB147 or a placebo for 12 weeks.

    Drug: BIIB147 · Drug: Placebo

  • Experimental
    MAD: Cohort D

    Participants will either receive Dose D of BIIB147 or a placebo for 20 weeks.

    Drug: BIIB147 · Drug: Placebo

  • Experimental
    OLE

    Participants from Cohorts A-D who complete the MAD period will enter a 4-week blinded loading-dose period. During this period, participants randomized to BIIB147 in the MAD period will receive placebo, followed by BIIB147, while participants randomized to placebo during the MAD period will receive BIIB147. Upon completion of the blinded loading-dose period, all participants will enter the open-label maintenance dose period and receive BIIB147 for up to 340 weeks.

    Drug: BIIB147 · Drug: Placebo

Interventions

  • DrugBIIB147

    Administered intrathecally (IT)

  • DrugPlacebo

    Administered IT

06

What researchers measure

Primary outcomes

  1. MAD, OLE, Integrated MAD and OLE Periods: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Week 416

Secondary outcomes

  1. MAD, OLE, Integrated MAD and OLE Periods: Serum Concentrations of Total Active BIIB147 Related Species

    Time frame: Pre-dose and at multiple time points post-dose [MAD: Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D); OLE and Integrated MAD and OLE: Up to Week 340

  2. MAD, OLE, Integrated MAD and OLE Periods: Cerebrospinal Fluid (CSF) Concentrations of Total Active BIIB147 Related Species

    Time frame: Pre-dose at multiple timepoints [MAD: Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D); OLE and Integrated MAD and OLE: Up to Week 340]

  3. MAD Period: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB147

    Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]

  4. MAD Period: Area Under the Serum Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-last) of BIIB147

    Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]

  5. MAD Period: Maximum Observed Serum Concentration (Cmax) of BIIB147

    Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]

  6. MAD Period: Time to Reach Maximum Observed Serum Concentration (Tmax) of BIIB147

    Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]

  7. MAD Period: Elimination Half-Life (t1/2) of BIIB147

    Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]

  8. MAD, Integrated MAD and OLE Periods: Change From Baseline in Plasma Concentration of Neurofilament Light Chain (NfL)

    Time frame: Baseline, Week 16 (Cohorts A, B, and C), Week 24 (Cohort D), and Up to Week 340 (Integrated MAD and OLE)

  9. Integrated MAD and OLE Period: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score

    Time frame: Baseline, Up to Week 340

  10. Integrated MAD and OLE Period: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC)

    Time frame: Baseline, Up to Week 340

  11. Integrated MAD and OLE Period: Change From Baseline in Muscle Strength as Measured by Handheld Dynamometry (HHD)

    Time frame: Baseline, Up to Week 340

  12. Integrated MAD and OLE Period: Change From Baseline in Bulbar Strength as Measured by Iowa Oral Pressure Instrument (IOPI)

    Time frame: Baseline, Up to Week 340

  13. Integrated MAD and OLE Period: Change From Baseline in Rasch Overall Amyotrophic Lateral Sclerosis (ALS) Disability (ROADS).

    Time frame: Baseline, Up to Week 340

  14. Integrated MAD and OLE Period: Change From Baseline in Weight

    Time frame: Baseline, Up to Week 340

  15. Integrated MAD and OLE Period: Time to Death or Permanent Ventilation

    Permanent ventilation is defined as ≥ 22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥ 21 consecutive days.

    Time frame: Up to Week 416

  16. Integrated MAD and OLE Period: Time to Death

    Time frame: Up to Week 416

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2034, 87 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 87 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Oct 7, 2026
Primary completionEst.
Jan 23, 2034
CompletionEst.
Jan 23, 2034
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • Washington University School of Medicine_St. Louis · St Louis, United States
  • Austin Neuromuscular Center_Austin · Austin, United States
  • Honor Health Neurology_Scottsdale · Scottsdale, United States
across 2 updates, Oct 19, 2026 – Nov 12, 2026
Start date
Oct 22, 2026→Oct 7, 2026 (actual)
Oct 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Washington University School of Medicine_St. Louis · St Louis, United StatesContact •••6981→•••2273Contact none listed→a•••@wustl.edu
Oct 26, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 4 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • Honor Health Neurology_Scottsdale · Scottsdale, United States
    + 1 other change: verification date
  2. Oct 26, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Washington University School of Medicine_St. Louis · St Louis, United StatesContact •••6981→•••2273Contact none listed→a•••@wustl.edu
  3. Oct 19, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Washington University School of Medicine_St. Louis · St Louis, United States
    • Austin Neuromuscular Center_Austin · Austin, United States
    Start date Oct 22, 2026→Oct 7, 2026 (now actual)
    + 1 other change: verification date
  4. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855211
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 7, 2026
Primary completion
Jan 23, 2034 (estimated)
Completion
Jan 23, 2034 (estimated)
Last update
Nov 12, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion